Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.
In a retrospective study of patients undergoing cranioplasty using OSSDSIGN Cranial, 96,7% of patients treated showed no signs of post-operative complications leading to implant removal at an average follow-up time of 9,5 months. This indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.
This preliminary data is part of a larger retrospective study which will be published and presented once completed. The preliminary data will be available in the OssDsign booth (#1) at EANS 2016 (the 16th European Congress of Neurosurgery, in Athens, Greece, 4th - 8th September 2016).
For more information, please contact OssDsign at firstname.lastname@example.org or www.ossdsign.com
TO THE EDITORS
About OSSDSIGN AB
OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects and deficits in skull, facial and other types of surgery. OssDsign has successfully launched its first patient specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany, the UK and the Nordic countries, and further global market expansion is ongoing.
By combining clinical insight with proprietary material technology and patient adapted design, OssDsign supplies an expanding range of tailored solutions for cranial repair and facial bone reconstruction. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. Main investors in OssDsign are Karolinska Development, SEB Venture Capital, Fouriertransform and Almi Invest
About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com